Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of pharmacy-benefit manager Express Scripts
So what: The shares have taken a beating on cost concerns associated with its proposed $29 billion buyout of rival MedcoHealth Solutions
Now what: Express Scripts remains a pretty attractive long-term opportunity. "In spite of near-term headwinds and a challenging macroeconomic environment," said Chairman and CEO George Paz, "we remain confident we are well-positioned for continued growth." In fact, the company's fiscal forecasts through 2014 -- disclosed in a securities filing on the merger -- were also much higher than analysts had expected, offering investors even more comfort regarding the Medco buy.
Interested in more info on Express Scripts? Add it to your watchlist.